Semorinemab (RG-6100) was under development for the treatment of mild to moderate Alzheimer’s disease. The drug candidate is administered through intravenous route which acts by targeting tau protein.
Richardson-based climate control solutions provider Lennox has been included in the S&P 500, a milestone it said recognizes the company’s sustained growth, innovation, and dedication to delivering ...